Elsevier

The Lancet

Volume 363, Issue 9426, 19 June 2004, Pages 2049-2051
The Lancet

Research Letters
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

https://doi.org/10.1016/S0140-6736(04)16456-8Get rights and content

Summary

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension. But inequalities in blood pressure, favouring amlodipine, throughout the multiyear trial precluded comparison of outcomes. A technique of serial median matching, applied at 6 months when treatment adjustments intended to achieve control of blood pressure were complete, created 5006 valsartan-amlodipine patient pairs matched exactly for systolic blood pressure, age, sex, and the presence or absence of previous coronary disease, stroke, or diabetes. Subsequent combined cardiac events, myocardial infarction, stroke, and mortality were almost identical in the two cohorts, but admission to hospital for heart failure was significantly lower with valsartan. Reaching blood pressure control (systolic <140 mm Hg) by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival.

Published online June 14, 2004 http://image.thelancet.com/extras/04let5020web.pdf

References (7)

  • S Julius et al.

    Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

  • JA Staessen et al.

    Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003

    J Hypertens

    (2003)
  • CD Furberg et al.

    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH AT)

    JAMA

    (2002)
There are more references available in the full text version of this article.

Cited by (0)

View full text